June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Modifiable and non-modifiable risk factors associated with primary open-angle glaucoma progression
Author Affiliations & Notes
  • Samuel Abokyi
    School of Optometry, The Hong Kong Polytechnic University Faculty of Health and Social Sciences, Kowloon, Hong Kong
    Optometry and Vision Science, University of Cape Coast, Cape Coast, Central , Ghana
  • SUMAILA ADAKUDUGU ISSAH
    Optometry and Vision Science, University of Cape Coast, Cape Coast, Central , Ghana
  • Footnotes
    Commercial Relationships   Samuel Abokyi Hong Kong Polytechnic University, University of Cape Coast, Code E (Employment); SUMAILA ISSAH None
  • Footnotes
    Support  Start-up Fund for RAPs under the Strategic Hiring Scheme (P0043215), PolyU (UGC).
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 1580. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Samuel Abokyi, SUMAILA ADAKUDUGU ISSAH; Modifiable and non-modifiable risk factors associated with primary open-angle glaucoma progression. Invest. Ophthalmol. Vis. Sci. 2023;64(8):1580.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Glaucoma is a leading cause of avoidable blindness globally. Early detection for treatment to reduce the intraocular ocular pressure (IOP) delays the progression of primary open-angle glaucoma (POAG), but that sometimes is not enough to preserve vision to outlast the lifespan of affected persons. The study investigated the modifiable and non-modifiable risk factors associated with POAG progression in patients from Ghana.

Methods : Two hundred and fifty diagnosed POAG patients with at least two reliable baseline and two follow-up 24-2 Visual Field tests over a period of 10 to 60 months were recruited for the evaluation of glaucoma progression. Ocular hypotensive drugs were the only form of treatment for all the POAG patients and none had undergone laser or surgery for glaucoma treatment. Using the International Physical Activity Questionnaire (IPAQ), the metabolic equivalent of task (MET) which is an objective measure of energy expenditure was evaluated. Patient biodata and information relating to baseline IOP, glaucoma stage, antiglaucoma drug, and medical history were collected from the medical record. Statistical analysis to determine risk factors of POAG progression was performed using binary logistic regression.

Results : The mean age (SD) of the glaucoma patients was 46.2 ±10.9 yr and comprised 136 males and 114 females. With a mean follow-up time of 2.1 ± 0.9 yr, glaucoma progression was found in 28 patients using Guided Progression Analysis. Of these, 20 (71.4%) were physically inactive (<300 MET-min/ week). Of these, 20 (71.4%) were physically inactive (<300 MET-min/ week). The patients with moderate physical activity (OR: 0.27, 95%CI:0.10-0.73, P=0.010) and high physical activity levels (OR: 0.08, 95%CI:0.01-0.66, P=0.019) were protected against glaucoma progression. The risk of progression was higher with advancing age and at early-stage POAG. Glaucoma progression, however, was independent of sex, baseline IOP, and antiglaucoma drug.

Conclusions : The study outcome indicates that higher physical activity is protective against the progression of primary open-angle glaucoma. Thus, primary open-angle glaucoma patients on antiglaucoma drugs to control IOP may adopt a physically active lifestyle to help further delay glaucoma progression. Prospective clinical trials on physical exercise as a neuroprotective intervention in primary open-angle glaucoma management are warranted.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×